$Moderna(MRNA.US) | UBS reiterates ๐๐๐ฎ๐ญ๐ซ๐๐ฅ on ๐๐๐๐, maintains ๐๐ ๐๐ญ $๐๐
Analyst sees the upcoming Phase III melanoma data as a major stock catalyst with a >50% chance of success, which would de-risk the INT program.
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments